ATE292640T1 - Therapeutische verbindungen gegen eierstockkrebs - Google Patents

Therapeutische verbindungen gegen eierstockkrebs

Info

Publication number
ATE292640T1
ATE292640T1 AT01939696T AT01939696T ATE292640T1 AT E292640 T1 ATE292640 T1 AT E292640T1 AT 01939696 T AT01939696 T AT 01939696T AT 01939696 T AT01939696 T AT 01939696T AT E292640 T1 ATE292640 T1 AT E292640T1
Authority
AT
Austria
Prior art keywords
ovarian cancer
therapeutic compounds
compounds against
against ovarian
compounds
Prior art date
Application number
AT01939696T
Other languages
English (en)
Inventor
Charles A Nicolette
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Application granted granted Critical
Publication of ATE292640T1 publication Critical patent/ATE292640T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4612—B-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4614—Monocytes; Macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Feed For Specific Animals (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT01939696T 2000-05-31 2001-05-30 Therapeutische verbindungen gegen eierstockkrebs ATE292640T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20938800P 2000-05-31 2000-05-31
US25700700P 2000-12-20 2000-12-20
PCT/US2001/017454 WO2001092306A2 (en) 2000-05-31 2001-05-30 Therapeutic compounds for ovarian cancer

Publications (1)

Publication Number Publication Date
ATE292640T1 true ATE292640T1 (de) 2005-04-15

Family

ID=26904120

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01939696T ATE292640T1 (de) 2000-05-31 2001-05-30 Therapeutische verbindungen gegen eierstockkrebs

Country Status (8)

Country Link
US (2) US6737062B2 (de)
EP (1) EP1284997B1 (de)
JP (1) JP2004503217A (de)
AT (1) ATE292640T1 (de)
AU (1) AU2001265188A1 (de)
CA (1) CA2410895A1 (de)
DE (1) DE60109922D1 (de)
WO (1) WO2001092306A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1355926A2 (de) * 2000-05-31 2003-10-29 Genzyme Corporation Therapeutische verbindungen für eierstockkrebs
ATE292640T1 (de) 2000-05-31 2005-04-15 Genzyme Corp Therapeutische verbindungen gegen eierstockkrebs
JP2005503118A (ja) * 2001-02-14 2005-02-03 ジェンザイム・コーポレーション 改変ペプチドリガンド
WO2002080845A2 (en) * 2001-04-04 2002-10-17 Genzyme Corporation Novel eps8 compounds for therapy and diagnosis and methods for using same
AU2002232563A1 (en) * 2001-12-05 2003-06-23 Genzyme Corporation Compounds for therapy and diagnosis and methods for using same
AU2003215193A1 (en) * 2002-02-11 2003-09-04 Joseph D. Mosca Production of a protein delivery system for in vivo therapeutic treatment
JP2005191530A (ja) * 2003-12-03 2005-07-14 Sumitomo Electric Ind Ltd 発光装置
US20110160130A1 (en) * 2007-02-16 2011-06-30 Connie Erickson-Miller Cancer treatment method
US20110129550A1 (en) 2007-02-16 2011-06-02 Connie Erickson-Miller Cancer treatment method
UY30915A1 (es) * 2007-02-16 2008-09-02 Smithkline Beecham Corp Método de tratamiento de canceres
CA2709224C (en) * 2007-10-09 2015-06-23 The Trustees Of The University Of Pennsylvania Thrombopoietin receptor agonist (tpora) kills acute human myeloid leukemia cells

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4754065A (en) 1984-12-18 1988-06-28 Cetus Corporation Precursor to nucleic acid probe
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5837249A (en) 1985-04-19 1998-11-17 The Wistar Institute Method for generating an immunogenic T cell response protective against a virus
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US5688657A (en) * 1988-03-31 1997-11-18 International Bio-Immune Systems, Inc. Monoclonal antibodies against human colon carcinoma-associated antigens and uses therefor
JPH06505486A (ja) 1991-02-07 1994-06-23 モレキュメティクス，リミティド βターンおよびβバルジのコンフォメーション的に制限された模倣物およびそれらを含有するペプチド
JPH07101999A (ja) 1993-10-06 1995-04-18 Hagiwara Yoshihide 抗癌ヒトモノクローナル抗体に対する抗イデイオタイプ抗体のアミノ酸配列およびそれをコードするｄｎａ塩基配列
US5643786A (en) 1995-01-27 1997-07-01 The United States Of America As Represented By The Department Of Health And Human Services Method for isolating dendritic cells
DE19817946A1 (de) 1998-04-17 1999-10-21 Metagen Gesellschaft Fuer Genomforschung Mbh Menschliche Nukleinsäuresequenzen aus Uterus-Normalgewebe
AU3395900A (en) 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides
AU2001233114A1 (en) 2000-02-04 2001-08-14 Aeomica, Inc. Methods and apparatus for predicting, confirming, and displaying functional information derived from genomic sequence
ATE292640T1 (de) 2000-05-31 2005-04-15 Genzyme Corp Therapeutische verbindungen gegen eierstockkrebs

Also Published As

Publication number Publication date
AU2001265188A1 (en) 2001-12-11
WO2001092306A2 (en) 2001-12-06
US6737062B2 (en) 2004-05-18
WO2001092306A3 (en) 2002-08-08
EP1284997B1 (de) 2005-04-06
EP1284997A2 (de) 2003-02-26
DE60109922D1 (de) 2005-05-12
JP2004503217A (ja) 2004-02-05
US20050048068A1 (en) 2005-03-03
CA2410895A1 (en) 2001-12-06
US20030175252A1 (en) 2003-09-18

Similar Documents

Publication Publication Date Title
FI1897548T4 (fi) T-solujen säätely
MX338940B (es) Identificacion de epitopos ige novedosos.
IL214325A (en) Antibody against cmet, a drug that includes and uses it
CY1115147T1 (el) Εξουδετερωτικα αντισωματα που εχουν ειδικοτητα για ανθρωπινη il-17
MX2016007865A (es) Peptidos citotoxicos y conjugados de los mismos.
TW200616661A (en) HER2 antibody composition
AU9399501A (en) Therapeutic antibodies
EP2570137A3 (de) Antikörper zur Bindung von humaner dendritischer und Epithelzelle 205 (DEC-205)
UA92505C2 (ru) Композиции на основе антитела против cd3
NO20061412L (no) Terapi av okulaere foretyrrelser
MX2007002675A (es) Antagonistas anti-beta7 humanizados y usos para los mismos.
CR11399A (es) ANTICUERPOS ANTI-IL-12/23p40, EPITOPES, FORMULACIONES, COMPOSICIONES, METODOS Y USOS
ATE292640T1 (de) Therapeutische verbindungen gegen eierstockkrebs
ATE497392T1 (de) Therapie mit anti-cd4-antikörpern und bestrahlung
IL163902A0 (en) Antibodies against cancer antigen tmeff2 and uses thereof
MX2021013657A (es) Conjugados de anticuerpo y farmaco.
WO2003104425A3 (en) NEW STABLE ANTI-CD22 ANTIBODIES
DE60238555D1 (de) Parathormon-antikörper und damit zusammenhängende verfahren
ATE313560T1 (de) Therapeutische anti-cytomegalovirus verbindungen
WO2001068677A3 (en) Derivatives of breast canacer antigen her-2 for therapeutical use
ATE297949T1 (de) Therapeutische verbindungen gegen eierstockkrebs
WO2001092307A3 (en) Therapeutic compounds for ovarian cancer
WO2002012272A3 (en) Therapeutic anti-melanoma compounds
WO2001070767A3 (en) Therapeutic anti-melanoma compounds
WO2003037264A3 (en) Therapeutic anti-hiv (vpr) compounds

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties